THESE GRAPHS ARE BASED ON INFORMATION COLLECTED THROUGH THE ACOR MCL WEBSITE AND ARE COPYRIGHTED

The hidden link to download the Sep 1, 2011 issue of the Excel spreadsheet is given in the Sept 1 ACOR email on this subject. The Excel list itself contains contains DX date and age and grouping for 521 MCL folks from ACOR and UCSD sites. Also treatment information is noted for most of the 521. Next issue is scheduled for Nov 1, 2011.

If you don't have Excel, you can download the free Excel viewer here which will let you open and view the above Excel file.

Fig 1. The treatment data, from our March 1 2010 Excel spreadsheet, is plotted above. As an example, out of 436 total MCL cases as of March 1, 2010, 340 had Rituxan (RITUX) monoclonal antibody biotherapy. Of these 340, 75 are known deceased and 265 are assumed living. The acual number of living is uncertain to the extent that 143 of the non-deceased have not reported on their condition in over 3 years- (THE ABOVE IS BASED ON THE MARCH 1, 2010 EXCEL SPREADSHEET).


Fig 2. On the average, those still surviving go to about 7 years from DX before the number reporting starts to significantly taper off. But the average DX age stays close to 50 to 60 yrs old up to 17 yrs from DX. After about 17 yrs survival the DX age of the few survivors tends to be less, but this would be true of many conditions. The results are probably also skewed because those that don't survive can't report this and their significant others may not be familiar with our web sites or may not choose to report such an event (THE ABOVE IS BASED ON THE MAR 1, 2010 EXCEL SPEADSHEET DATA ).

Fig 3. This plot shows that 10 years ago, the CHOP TX was 4 times more popular than the HCVAD TX. Now, the HCVAD through 2008 is used almost twice as much as CHOP. There appears to be somewhat more CHOP use in 2009 for unknown reasons. Both TXs started adding Rituxan after about year 2000 (THE ABOVE IS BASED ON THE MARCH 1, 2010 EXCEL SPEADSHEET DATA). Happy Easter.